Clinical Trial Update: A Study LY2228820 for Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for LY2228820 in recurrent ovarian cancer (epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer) comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• LY2228820 (LY2228820)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-05-29